Table 2.

Inclusion and exclusion criteria for study participation

Inclusion criteria

Exclusion criteria

Individuals aged 18 years and older Diagnosis of mild to moderate plaque-type psoriasis, confirmed by a board-certified dermatologist, with a psoriasis area and severity index (PASI) score of less than ten Presence of two or more psoriatic plaques, each with a size no larger than 5*5 cm2, of similar size and severity Abstinence from any topical psoriasis treatments for a minimum of 2 weeks prior to the initiation of the study Capability and willingness to provide written informed consent for participation in the research

Current pregnancy or breastfeeding status Known contraindications to the use of cannabis transdermal patches, such as allergies to medical cannabis or any components of the patches, severe liver or kidney disease, or a history of schizophrenia or other significant psychiatric conditions Evidence of addictive behavior, including abuse of cannabis, opioids, or other recreational or prescription drugs, as determined through patient interviews and medical records Ongoing treatment with biologic therapies specifically for psoriasis Recent (less than 12 weeks prior to study start) or ongoing treatment with conventional systemic therapies for psoriasis (oral medications or phototherapy) without stable disease status or alterations in treatment regimen within the last 12 weeks